Panaxadiol
Based on 4 publication(s) in Google Scholar
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.
For research use only. We do not sell to patients.
- Purity : 99.89%
- CAS No.: 19666-76-3
- Formula: C30H52O3
- Molecular Weight:460.73
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N0220
DauricineApoptosis Inducer -
HY-N0242
FraxinelloneSTAT Inhibitor -
HY-N0596R
Panaxadiol (Standard)HIF-1α/STAT3 Inhibitor -
HY-N0790
LupeolAndrogen Receptor Inhibitor -
HY-N0140
Ursolic acidAutophagy Inducer -
HY-N0615
Notoginsenoside R1Apoptosis Inhibitor -
HY-B0233
IsradipineL-type Calcium Channel Blocker -
HY-101093
CA-170VISTA/PD-L1 Inhibitor -
HY-N0790R
Lupeol (Standard)Androgen Receptor Inhibitor -
HY-N0039
Ginsenoside Rb1Autophagy Inducer -
HY-N0387
RhynchophyllineNF-κB Inhibitor -
HY-N0140R
Ursolic acid (Standard)Autophagy Inducer
Publications Citing Use of MedChemExpress (MCE) Panaxadiol
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
43.13 μM
Compound: PD
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21439693] |
| A549 | IC50 |
44.57 μM
Compound: PD
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30568759] |
| HeLa | IC50 |
>100 μM
Compound: PD
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30568759] |
| Hep 3B2 | IC50 |
31.7 μM
Compound: PD
|
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay
|
[PMID: 33130293] |
| HepG2 | IC50 |
37.91 μM
Compound: PD
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21439693] |
| MCF7 | IC50 |
52.62 μM
Compound: PD
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30568759] |
| U2OS | IC50 |
26.81 μM
Compound: PD
|
Cytotoxicity against human U2OS cells after 48 hrs by MTT assay
Cytotoxicity against human U2OS cells after 48 hrs by MTT assay
|
[PMID: 21439693] |
| U-87MG ATCC | IC50 |
>100 μM
Compound: PD
|
Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30568759] |
In Vitro
Panaxadiol (1-10 μM, 12 h) inhibits PD-L1 expression in human colon cancer cells[1].
Panaxadiol (1-10 μM, 12 h) inhibits the expression of PD-L1 by suppressing HIF-1α and STAT3 in HCT116 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116, SW620 and HT-29 colon cancer cells
-
Concentration:1, 3, and 10 μM
-
Incubation Time:12 hours
-
Result:Decreased the expression of PD-L1 protein and mRNA in a dose-dependent manner.
-
Cell Line:HCT116 cells
-
Concentration:1, 3, and 10 μM
-
Incubation Time:12 hours
-
Result:Inhibited hypoxia-induced nuclear accumulation of HIF-1α in a dose-dependent manner.
Inhibited STAT3 phosphorylation at Tyr705 in a dose-dependent manner under both normoxic and hypoxic conditions.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c athymic nude mice injected with HCT116 cells[1]
-
Dosage:10 or 30 mg/kg
-
Administration:Oral gavage; 10 or 30 mg/kg; once every 3 days; 30 days
-
Result:Inhibited the protein levels of HIF-1α, p-STAT-3 (Tyr705), PD-L1 and VEGF in tumour tissues in a dose-dependent manner.
Chemical Information
-
CAS No. 19666-76-3
-
Appearance Solid
-
Molecular Weight 460.73
-
Formula C30H52O3
-
Color White to off-white
-
SMILES
C[C@@]1(CC[C@@H]2O)[C@](C[C@H]3O)([H])[C@](CC[C@@]1([H])C2(C)C)(C)[C@@]4(C)[C@@]3([H])[C@]([C@](CCC5)(C)OC5(C)C)([H])CC4
-
Synonyms
20(R)-Panaxadiol
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
Ginsenoside (20)S-APPT induces ferroptosis in hepatocellular carcinoma and cholangiocarcinoma by targeting FSP1. [Abstract]2025 Jun 23. PMID: 40550962 -
Drug Dev Res
Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage. [Abstract]2025 Apr;86(2):e70079. PMID: 40117294 -
Exp Cell Res
CMTM4 promotes PD-L1-mediated macrophage apoptosis by enhancing STAT2 phosphorylation in sepsis. [Abstract]2025 Apr 15;447(2):114519. PMID: 40122504 -
Gene
Panaxadiol inhibits the proliferation and immune evasion of esophageal squamous cell carcinoma cells by suppressing HIF-1α/STAT3/PD-L1 pathway. [Abstract]2025 Oct 23:149829. PMID: 41138756
Solvent & Solubility
In Vitro:
Ethanol : 20 mg/mL (43.41 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (4.34 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2 mg/mL (4.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang Z, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727. [Content Brief]
[2]. Myong Hak Ri, et al. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol. 2021 Dec 5;281:114370. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.1705 mL | 10.8523 mL | 21.7047 mL | 54.2617 mL |
| 5 mM | 0.4341 mL | 2.1705 mL | 4.3409 mL | 10.8523 mL | |
| 10 mM | 0.2170 mL | 1.0852 mL | 2.1705 mL | 5.4262 mL | |
| 15 mM | 0.1447 mL | 0.7235 mL | 1.4470 mL | 3.6174 mL | |
| 20 mM | 0.1085 mL | 0.5426 mL | 1.0852 mL | 2.7131 mL | |
| 25 mM | 0.0868 mL | 0.4341 mL | 0.8682 mL | 2.1705 mL | |
| 30 mM | 0.0723 mL | 0.3617 mL | 0.7235 mL | 1.8087 mL | |
| 40 mM | 0.0543 mL | 0.2713 mL | 0.5426 mL | 1.3565 mL |
Panaxadiol Related Classifications
HY-N0596 Related Classifications
Powered by Bioz